Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from MedAdvisor Limited ( (AU:MDR) ) is now available.
MedAdvisor Limited has completed the sale of its ANZ business operations and related intellectual property to Jonas Software for an estimated total transaction value of $42.35 million. This strategic move allows MedAdvisor to focus on its US operations while maintaining its ASX listing. The transaction involves a $35 million headline price, with an additional earn-out potential of $7.35 million based on future performance. The sale will enable MedAdvisor to discharge its financial obligations and marks a significant shift in its operational focus. Additionally, the company’s CFO, Mrs. Ancila Desai, will be stepping down following the transaction.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Limited operates in the healthcare technology industry, providing medication management solutions. The company focuses on enhancing patient health outcomes through its digital platforms, primarily serving markets in Australia, New Zealand, and the United States.
Average Trading Volume: 905,713
Technical Sentiment Signal: Sell
Current Market Cap: A$34.36M
Find detailed analytics on MDR stock on TipRanks’ Stock Analysis page.